Medtronic plc, a leader in medical device manufacturing, presents a stable investment opportunity with a balanced risk-reward profile. The company has shown consistent performance across its fundamental scores, indicating potential for steady long-term returns. Analysts have predominantly positive outlooks on MDT, though market dynamics in the healthcare sector should be closely monitored.
Medtronic plc exhibits a strong fundamental profile with a "B+" rating, indicating a solid performance across various financial metrics.
Category | Score | Visual |
---|---|---|
Discounted Cash Flow | 4 | |
Return on Equity | 4 | |
Return on Assets | 4 | |
Debt to Equity | 1 | |
Price to Earnings | 2 | |
Price to Book | 3 |
Recent historical data shows stability in Medtronic's ratings, with overall scores remaining consistent over time.
Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-09-26 | 3 | 4 | 4 | 4 | 1 | 2 | 3 |
N/A | 0 | 4 | 4 | 4 | 1 | 2 | 3 |
The analysts' consensus is positive with a consistent target across high, low, median, and consensus prices.
High | Low | Median | Consensus |
---|---|---|---|
115 | 115 | 115 | 115 |
Analyst recommendations show a strong buy and buy preference for MDT, indicating a confidence in its stock performance.
Recommendation | Count | Proportion |
---|---|---|
Strong Buy | 1 | |
Buy | 27 | |
Hold | 21 | |
Sell | 0 | |
Strong Sell | 0 |
Medtronic plc stands as a notable contender in the medical devices sector with consistent fundamentals indicating potential stability and growth. Despite a solid debt-to-equity ratio, its other financial metrics remain robust. With largely positive analyst ratings, MDT is poised for future growth, though an eye should be kept on market shifts within the healthcare sector. Investors may find MDT particularly appealing for its stable returns and strong buy recommendations.